Bactiguard Holding AB reported total revenue of SEK 65.6 million for the fourth quarter (Q4) of 2025, representing a decrease of 3.9%. Net sales for the quarter reached SEK 63.2 million, while operating profit stood at SEK 13.0 million. EBITDA for the quarter amounted to SEK 24.7 million. Net profit for the period was SEK 12.5 million, with profit per share before and after dilution at SEK 0.36. Cash flow from operating activities totaled SEK 11.7 million. For the full year (FY) 2025, total revenue was SEK 228.8 million, reflecting a decrease of 12.6%. The Board of Directors has proposed that no dividend will be paid for the 2025 fiscal year. During the period, Bactiguard continued its transition towards a partnership business model, strengthening relationships with existing partners and progressing discussions with leading MedTech companies. The company highlighted stable revenue from its license business, an updated agreement with Zimmer Biomet contributing to Q4 growth, and a more than doubling of full-year EBITDA, resulting in an EBITDA margin of 19 percent. Cost reductions of over 25 percent were achieved, despite continued investments in the core license business. Looking ahead, Bactiguard aims to further develop new business partnerships, support sales growth of Bactiguard-coated products, and enhance operational efficiency in 2026, with a focus on double-digit revenue growth in the Wound Management portfolio.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bactiguard Holding AB published the original content used to generate this news brief via Cision (Ref. ID: 20260204:BIT:6303:0) on February 05, 2026, and is solely responsible for the information contained therein.